Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats
Joint Authors
Abubakari, Abdul-Razak
Itua, Imose
Naderali, Ebrahim K.
Naderali, Mohammad M.
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-08-21
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Pharmacy, Health & Medical Sciences
Pharmacology
Abstract EN
A number of preclinical and clinical studies have reported blood-pressure-lowering benefits of thiazolidinediones in diabetic subjects and animal models of diabetes.
This study was designed to further elucidate vascular effects of rosiglitazone, on healthy nonobese, lean animals.
Adult male Wistar rats were randomized and assigned to control and rosiglitazone-treated groups and were dosed daily with either vehicle or rosiglitazone (10 mg kg−1 day−1) by oral gavage for 5 days.
Compared with control group, rosiglitazone treatment significantly reduced plasma levels of triglycerides (>240%) and nonesterified free fatty acids (>268%) (both, P<0.001).
There were no changes in vascular contractility to KCl or noradrenaline between two groups.
However, rosiglitazone therapy improved carbamylcholine-induced vasorelaxation (93±3 % versus control 78±2, P<0.01) an effect which was abolished by L-NAME.
There was no difference in sodium nitroprusside-induced vasorelaxation between the control and rosiglitazone-treated animals.
These results indicate that short-term rosiglitazone therapy improves both metabolic profile and vascular function in lean rats.
The vascular effect of rosiglitazone appears to be mediated by alteration in NO production possibly by activation of endothelial PPARγ.
This increased NO production together with improved lipid profile may explain mechanism(s) of blood-pressure-lowering effects of thiazolidinediones on both human and experimental animals.
American Psychological Association (APA)
Naderali, Mohammad M.& Itua, Imose& Abubakari, Abdul-Razak& Naderali, Ebrahim K.. 2012. Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats. ISRN Pharmacology،Vol. 2012, no. 2012, pp.1-7.
https://search.emarefa.net/detail/BIM-448066
Modern Language Association (MLA)
Naderali, Mohammad M.…[et al.]. Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats. ISRN Pharmacology No. 2012 (2012), pp.1-7.
https://search.emarefa.net/detail/BIM-448066
American Medical Association (AMA)
Naderali, Mohammad M.& Itua, Imose& Abubakari, Abdul-Razak& Naderali, Ebrahim K.. Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats. ISRN Pharmacology. 2012. Vol. 2012, no. 2012, pp.1-7.
https://search.emarefa.net/detail/BIM-448066
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-448066